Curaleaf Holdings, Inc.
CURLF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CURLF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.76B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Run Curaleaf Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Curaleaf Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 2.65
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$233K
| Holder | Shares | Value |
|---|---|---|
| albert d mason inc | 75,079 | $161K |
| nano cap new millennium growth fund l p | 32,500 | $70K |
| mark sheptoff financial planning, llc | 800 | $3K |
| ancora advisors llc | 100 | $214 |
| nbc securities, inc. | 22 | $47 |
Governance
Frequently asked questions
Who is the CEO of Curaleaf Holdings, Inc.?
Mr. Boris Alexis Jordan is the chief executive officer of Curaleaf Holdings, Inc. (CURLF).
Where is Curaleaf Holdings, Inc. headquartered?
Curaleaf Holdings, Inc. (CURLF) is headquartered in Stamford, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.